Jacob Plieth

Podcast – a new audio formulation for our PD(L)anner - Evaluate Pharma

After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.

However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.

Ferring’s Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.

The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.

39% of the patients assessed carried this biomarker, the conference presentation reveals.

Readout of Tropion-Lung01, testing the most advanced indication for datopotamab, could lead to a first-half US filing.

Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.

JP Morgan 2023 – licensing deal flurry offers limited cash up front - Evaluate Pharma

Propelled by Covid Pfizer surges ahead, but more interest could fall on a cohort of companies driven by newcomer drugs lower down the list.

Propelled by Covid Pfizer surges ahead, but more interest could fall on a cohort of companies driven by newcomer drugs lower down the list.

A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.

The Arc-7 trial might be a numerical success, but Roche’s experience will weigh heavy.

Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.

Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.

Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.

Roche and Bristol Myers Squibb look to have the industry’s next most advanced assets against GPRC5D.

Gilead has licensed CART-ddBCMA as this cell therapy continues putting all patients into remission. Can it compete against Carvykti and Tecvayli?

The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.

Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.